🔗 Permalink

Assignee profile:

Cytlimic Inc.

City:

Tokyo

Country:

Japan

Published Applications:

Last publication date:

2022-06-23

Patent Grants:

Last grant date:

2023-09-19

Top Inventors for applications by Cytlimic Inc.

These are the the leading inventors for applications assigned to Cytlimic Inc.:

Tomoya MIYAKAWA 10 Tokyo, Japan
Koji TAMADA 10 Yamaguchi, Japan
Masaaki OKA 6 Yamaguchi, Japan
Shoichi HAZAMA 6 Yamaguchi, Japan

Keiko Udaka 6 Kochi, Japan
Shun Doi 4 Tokyo, Japan

Recent patent applications by Cytlimic Inc.

Cytlimic Inc. based in Tokyo, JP has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-06-23

US20220193213A1

Human necessities

HSP70-DERIVED PEPTIDE, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING SAME, IMMUNITY INDUCER, AND METHOD FOR PRODUCING ANTIGEN PRESENTING CELL

#2 | 2022-06-09 ✅ Patent 11,759,518 granted on 2023-09-19

US20220175915A1

Human necessities

Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein

#3 | 2021-01-07 ✅ Patent 11,491,204 granted on 2022-11-08

US20210000916A1

Human necessities

Composition comprising poly I:C and LAG-3-IGG fusion protein

#4 | 2020-05-21 ✅ Patent 10,875,900 granted on 2020-12-29

US20200157163A1

Chemistry; metallurgy

Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

#5 | 2020-04-23 ✅ Patent 11,304,997 granted on 2022-04-19

US20200121772A1

Human necessities

HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell

#6 | 2020-02-06 ✅ Patent 11,291,718 granted on 2022-04-05

US20200038508A1

Human necessities

Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein

#7 | 2019-02-28 ✅ Patent 10,590,179 granted on 2020-03-17

US20190062389A1

Chemistry; metallurgy

Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

#8 | 2018-06-21 ✅ Patent 10,537,626 granted on 2020-01-21

US20180169199A1

Human necessities

HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell

#9 | 2018-04-19 ✅ Patent 10,526,388 granted on 2020-01-07

US20180105567A1

Chemistry; metallurgy

Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells

#10 | 2018-03-15 ✅ Patent 10,842,848 granted on 2020-11-24

US20180071362A1

Human necessities

Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein

Also check out CYTLIMIC INC.'s (Tokyo, Japan) applicant profile with 6 patent applications submitted.

AssigneeID:

136241 ⎘